Dotenorad solid dispersion, solid dispersion pharmaceutical composition, preparation method and application and medicine containing solid dispersion
Dotenorazole solid dispersion was prepared by compounding povidone K90 with poloxamer 407 and using spray drying technology. This solved the problems of low solubility and poor stability of dotenorazole, and achieved rapid dissolution and high bioavailability, making it suitable for industrial production.
Patent Information
- Application Number
- CN202511366360.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-17
- Publication Date
- 2025-12-12
AI Technical Summary
Dotenorazole, as a BCS Class II drug, has low solubility, leading to incomplete absorption and low bioavailability. Furthermore, its slow dissolution in the gastrointestinal tract may cause adverse reactions. In addition, traditional preparation processes make it difficult to stabilize its amorphous form, affecting clinical efficacy and product consistency.
Dotenoramide solid dispersion was prepared by spray drying technology using a compound of povidone K90 and poloxamer 407. Povidone K90 was used as a stable framework and poloxamer 407 was used as a solubilizer to rapidly capture and solidify dotenoramide into an amorphous form, forming a highly efficient dispersion system.
It achieves rapid dissolution and improved stability of dotenorazole, increases bioavailability, reduces gastrointestinal irritation, and is suitable for industrial production.
Smart Images

Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical formulation technology, and more particularly to dotenoroxetine solid dispersions, solid dispersion pharmaceutical compositions, preparation methods, and applications in pharmaceuticals containing solid dispersions. Background Technology
[0002] Gout is a metabolic disease caused by a disorder of purine metabolism, leading to a persistently elevated level of uric acid (UA) in the blood, resulting in the deposition of urate crystals (MSU) in joints, soft tissues, and kidneys. Clinical manifestations include hyperuricemia, recurrent acute arthritis, and long-term complications such as joint deformities and kidney damage.
[0003] Dotinurad is a novel, highly effective, selective uric acid reabsorption transporter 1 (URAT1) inhibitor. It effectively lowers serum uric acid levels by inhibiting renal reabsorption of uric acid, making it a potential treatment for gout and hyperuricemia. However, dotinurad belongs to Class II in the Biopharmaceutical Classification System (BCS), characterized by low solubility and high permeability. Its extremely low solubility in water leads to slow dissolution in the gastrointestinal tract after oral administration of its conventional dosage forms (such as regular tablets), resulting in incomplete absorption and low bioavailability, thus affecting the stability and predictability of clinical efficacy. Furthermore, the slow dissolution in the gastrointestinal tract may create areas of high concentration, irritating the gastrointestinal mucosa and causing adverse reactions such as nausea and abdominal pain.
[0004] Solid dispersion technology is a recognized effective method in the field for improving the solubility of such poorly soluble drugs. However, developing dotenoroxetine into a stable and effective solid dispersion faces dual challenges stemming from its own physicochemical properties and preparation process, specifically as follows: Limitations inherent in the drug's properties: Dotenoradine has a high melting point (approximately 224°C) and strong crystallization energy, meaning it tends to form highly ordered and stable crystalline structures in the solid state. This leads to two direct technical challenges: first, transforming the drug into a high-energy amorphous state requires overcoming a significant energy barrier; second, once formed in an amorphous state, drug molecules have a strong spontaneous tendency to recrystallize back to a lower-energy, stable crystalline state. This physical instability is the most critical risk of failure in the development of amorphous solid dispersion formulations.
[0005] The contradiction between drug-carrier compatibility and stability: An ideal carrier needs to have good thermodynamic compatibility with drug molecules, usually "locking" the drug molecules in through interactions such as hydrogen bonds to inhibit crystallization. However, for molecules like dotenoradine, achieving both good compatibility and long-term physical stability under high drug loading is extremely challenging. When selecting a carrier, one often sacrifices one for the other in terms of solubilization and stabilization. After long-term storage, amorphous drugs are prone to recrystallization, leading to a sharp drop in dissolution.
[0006] Limitations of traditional preparation processes: Traditional processes for preparing solid dispersions include solvent evaporation. This method has a long process flow. More importantly, the slow solvent evaporation process gives drug molecules enough time to rearrange, making it difficult to effectively "capture" and stabilize their high-energy amorphous form. The product dissolution improvement effect and batch-to-batch consistency are not ideal, making it unsuitable for large-scale production. Summary of the Invention
[0007] The purpose of this invention is to provide dotenoroxetine solid dispersion, solid dispersion pharmaceutical composition, preparation method, and application to drugs containing solid dispersion. The dotenoroxetine solid dispersion prepared by the method of this invention has fast dissolution, good stability, and is suitable for large-scale production.
[0008] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a method for preparing a dotenoroxetine solid dispersion, comprising the following steps: Dotenorazole, povidone K90, and poloxamer 407 were dissolved in water and a pharmaceutical organic solvent to obtain a mixed solution; the mass ratio of povidone K90 to poloxamer 407 was >1. The mixed solution was spray-dried to obtain the dotenoroxetine solid dispersion.
[0009] Preferably, the mass ratio of povidone K90 to poloxamer 407 is 10~40:1.
[0010] Preferably, the mass ratio of dotenorazole to the total mass of povidone K90 and poloxamer 407 is 1:5~9.
[0011] Preferably, the pharmaceutical organic solvent includes ethanol, and the volume ratio of the pharmaceutical organic solvent to water is 2.0~2.5:1; the total mass fraction of dotenorazole, povidone K90 and poloxamer 407 in the mixed solution is 10~20%.
[0012] Preferably, the spray drying conditions include: an inlet air temperature of 95~105℃, a feed rate of 4~6mL / min, and an atomizing gas pressure of 180~220kPa.
[0013] The present invention provides a dotenoroxetine solid dispersion prepared by the preparation method described in the above technical solution.
[0014] The present invention provides a solid dispersion pharmaceutical composition comprising the dotenoroxetine solid dispersion described above and at least one pharmaceutically acceptable excipient.
[0015] This invention provides the use of the above-described dotenoradine solid dispersion or the solid dispersion pharmaceutical composition described above in the preparation of drugs for the treatment of gout and / or hyperuricemia.
[0016] This invention provides a drug containing a solid dispersion, the raw materials for which include the dotenoroxetine solid dispersion described in the above technical solution or the solid dispersion drug composition described in the above technical solution, wherein the drug containing the solid dispersion is an oral drug.
[0017] Preferably, the dosage form of the drug containing the solid dispersion includes tablets or capsules.
[0018] This invention provides a method for preparing a dotenoroxetine solid dispersion, comprising the following steps: dissolving dotenoroxetine, povidone K90, and poloxamer 407 in water and a pharmaceutical organic solvent to obtain a mixed solution; wherein the mass ratio of povidone K90 to poloxamer 407 is >1; and spray-drying the mixed solution to obtain the dotenoroxetine solid dispersion. This invention utilizes a combination of povidone K90 and poloxamer 407, where povidone K90 acts as a high molecular weight backbone carrier and poloxamer 407 acts as a highly efficient micellar solubilizer, resulting in a synergistic effect greater than the sum of its parts (1+1>2). Specifically, povidone K90 acts as a "stabilizing backbone," using its long-chain network and hydrogen bonding to "anchor" dotenoroxetine molecules in a high-energy amorphous state, fundamentally ensuring the physical stability of the solid dispersion during its shelf life. Poloxamer 407, acting as a "highly efficient solubilizing engine," functions as a highly efficient wetting agent in solid dispersions, exerting a micellar solubilizing effect during the dissolution of dotenoramide, achieving both "instant wetting" and "continuous solubilization." The synergistic effect of povidone K90 and poloxamer 407 enables a qualitative leap in the dissolution behavior of dotenoramide. Simultaneously, this invention employs a spray drying process, based on a highly efficient "kinetic capture" mechanism. During spray drying, droplets containing dotenoramide, povidone K90, and poloxamer 407 experience rapid solvent evaporation upon contact with hot air (within milliseconds). This "quenching" process prevents dotenoroxetine from arranging itself into an ordered lattice before it is "frozen" in a high-energy amorphous state and tightly encapsulated by the solidified povidone K90 carrier. This rapid capture in kinetics is the most effective means of overcoming the high crystallization energy of dotenoroxetine and forming a pure amorphous state. Furthermore, the spray drying process ensures that dotenoroxetine is uniformly dispersed in the povidone K90 matrix as individual molecules or very small aggregates, forming an excellent molecular-level dispersion system, which is a prerequisite for achieving maximum dissolution potential. Therefore, the dissolution effect and stability of the dotenoroxetine solid dispersion prepared by the method of this invention are far superior to the slow solvent evaporation method.
[0019] Furthermore, the spray drying conditions described in this invention include: an inlet air temperature of 95~105℃, a feed rate of 4~6mL / min, and an atomizing gas pressure of 180~220kPa. This invention achieves one-step molding under mild drying conditions through spray drying. Specifically, although the inlet air temperature in the spray drying process of this invention is relatively high, the rapid evaporation of the solvent removes a large amount of heat (evaporative cooling effect), and the actual temperature of the droplets themselves is much lower than the inlet air temperature, effectively avoiding thermal degradation of the drug. Simultaneously, this spray drying process integrates dissolution, dispersion, drying, and granulation into one process, which is simple and efficient. The resulting dotenoxetine solid dispersion has good flowability, making it easy to further process into drugs, such as tablets, through compression, perfectly meeting the needs of large-scale industrial production. Detailed Implementation
[0020] This invention provides a method for preparing a dotenoroxetine solid dispersion, comprising the following steps: Dotenorazole, povidone K90, and poloxamer 407 were dissolved in water and a pharmaceutical organic solvent to obtain a mixed solution; the mass ratio of povidone K90 to poloxamer 407 was >1. The mixed solution was spray-dried to obtain the dotenoroxetine solid dispersion.
[0021] The preparation process of the dotenoroxetine solid dispersion in this invention is simple, the product dissolves quickly, has good stability, and can effectively improve the bioavailability of dotenoroxetine, meeting the requirements of industrial production. The preparation method of the dotenoroxetine solid dispersion in this invention is described in detail below.
[0022] In this invention, unless otherwise specified, all raw materials used are commercially available products well known to those skilled in the art or prepared using methods well known to those skilled in the art.
[0023] This invention dissolves dotenoroxetine, povidone K90, and poloxamer 407 in water and a pharmaceutical organic solvent to obtain a mixed solution. The mass ratio of povidone K90 to poloxamer 407 in this invention is >1, further preferably 5-45, and even more preferably 10-40:1, specifically 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, or 40:1. This invention uses a combination of povidone K90 and poloxamer 407 to prepare a dotenoroxetine solid dispersion, resulting in excellent dissolution of dotenoroxetine. If poloxamer 407 is not used or its mass proportion is too high, the dissolution rate and amount of dotenoroxetine will be significantly reduced.
[0024] In one embodiment of the present invention, the mass ratio of dotenorazole to the total mass of povidone K90 and poloxamer 407 (i.e., drug loading ratio) can be 1:5 to 9, specifically 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.2, or 1:9. In another embodiment of the present invention, the pharmaceutical organic solvent includes ethanol, and the ethanol used in this embodiment has a purity of 95 vol%; the volume ratio of the pharmaceutical organic solvent to water can be 2.0 to 2.5:1, specifically 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5; the total mass fraction of dotenorazole, povidone K90, and poloxamer 407 in the mixed solution can be 10 to 20%, specifically 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%.
[0025] As one embodiment of the present invention, the method of dissolving dotenoradine, povidone K90 and poloxamer 407 in water and pharmaceutical organic solvent includes: mixing water and pharmaceutical organic solvent to obtain a mixed solvent; mixing povidone K90 and poloxamer 407 with the mixed solvent and stirring until completely dissolved; then adding dotenoradine and stirring continuously at 30~35°C until completely dissolved to obtain the mixed solution.
[0026] After obtaining the mixed solution, the present invention performs spray drying on the mixed solution to obtain the dotenoroxetine solid dispersion. As one embodiment of the present invention, the spray drying conditions include: an inlet air temperature of 95~105℃, specifically 100℃; a feed rate of 4~6 mL / min, specifically 5 mL / min; and an atomizing gas pressure of 180~220 kPa, specifically 200 kPa. Specifically, in this embodiment of the present invention, the spray drying is performed in a spray dryer.
[0027] After spray drying, the present invention preferably further includes passing the collected powder through an 80-mesh sieve and collecting the material under the sieve to obtain the dotenoroxetine solid dispersion.
[0028] The present invention provides a dotenoroxetine solid dispersion prepared by the preparation method described in the above technical solution.
[0029] The present invention provides a solid dispersion pharmaceutical composition comprising the dotenoroxetine solid dispersion described above and at least one pharmaceutically acceptable excipient.
[0030] As one embodiment of the present invention, the pharmaceutically acceptable excipients may include fillers, disintegrants, and lubricants. Specifically, the solid dispersion pharmaceutical composition of the present invention may include the following components by mass parts: 10-20 parts of dotenoradine solid dispersion; 60-100 parts of filler; 5-15 parts of disintegrant; and 1-3 parts of lubricant.
[0031] The solid dispersion pharmaceutical composition of the present invention comprises 10 to 20 parts of dotenorazole solid dispersion, specifically 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 parts by weight.
[0032] Based on the mass fraction of the dotenoroxetine solid dispersion, the solid dispersion pharmaceutical composition of the present invention comprises 60-100 parts of filler, specifically 60, 68, 75, 80, 85, 90, 98, or 100 parts. The filler of the present invention may include one or more of microcrystalline cellulose, lactose, and mannitol, specifically microcrystalline cellulose.
[0033] Based on the mass fraction of the dotenoroxetine solid dispersion, the solid dispersion pharmaceutical composition of the present invention includes 5 to 15 parts of disintegrant, specifically 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 parts. The disintegrant of the present invention may include one or more of croscarmellose sodium, carboxymethyl starch sodium, and croscarmellose, specifically croscarmellose sodium.
[0034] Based on the mass fraction of the dotenoroxetine solid dispersion, the solid dispersion pharmaceutical composition of the present invention includes 1 to 3 parts of lubricant, specifically 1 part, 1.5 parts, 2 parts, 2.5 parts, or 3 parts. The lubricant of the present invention may include one or more of magnesium stearate, stearic acid, and calcium stearate, specifically magnesium stearate.
[0035] This invention provides the use of the dotenoradine solid dispersion or the solid dispersion pharmaceutical composition described in the above-described technical solutions in the preparation of a treatment for gout and / or hyperuricemia. As one embodiment of this invention, the treatment is preferably an oral medication, and the dosage form of the treatment may include tablets or capsules.
[0036] This invention provides a drug containing a solid dispersion, the raw materials for which include the dotenoroxetine solid dispersion described in the above technical solution or the solid dispersion drug composition described in the above technical solution, wherein the drug containing the solid dispersion is an oral drug.
[0037] As one embodiment of the present invention, the dosage form of the drug containing the solid dispersion may include tablets or capsules.
[0038] As one embodiment of the present invention, the preparation method of the tablet may include the following steps: mixing dotenololide solid dispersion, microcrystalline cellulose, croscarmellose sodium and magnesium stearate, and compressing the resulting mixture into tablets to obtain the tablets (i.e., dotenololide tablets); each tablet may contain 2 mg of dotenololide.
[0039] The technical solutions of this invention will be clearly and completely described below with reference to the embodiments thereof. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.
[0040] The materials and instruments used in the following experiments are as follows: Active ingredient: Dotenorazole (Shandong Jikun Biopharmaceutical Co., Ltd.)
[0041] Excipients: Povidone K90 (PVP K90, Kollidon® 90), BASF (China) Co., Ltd.; Poloxamer 407 (Poloxamer 188, Kollidon® P 407), BASF (China) Co., Ltd.; Hydroxypropyl methylcellulose (HPMC, E5 type), Anhui Shanhe Pharmaceutical Excipients Co., Ltd.; Sodium dodecyl sulfate (SLS), Sinopharm Chemical Reagent Co., Ltd.; Microcrystalline cellulose (MCC, PH102), Jiangxi Xidian Pharmaceutical Excipients Co., Ltd.; Croscarmellose sodium cellulose (CCNa), Beijing Nikirin Chemical Industries, Ltd.; Magnesium stearate, Anhui Shanhe Pharmaceutical Excipients Co., Ltd.; Pharmaceutical grade ethanol (95% by volume), Shandong Longyuquan Pharmaceutical Excipients Co., Ltd.; Purified water, in-house prepared.
[0042] Instruments: Spray dryer (SD220, Shenzhen Xinyite Technology Co., Ltd.). Dissolution tester (RCZ-8M, Tianjin Tianda Tianfa Technology Co., Ltd.). High performance liquid chromatograph (HPLC, Agilent 1260, Agilent Technologies, Inc.).
[0043] Example 1 The formulation of dotenoroxetine solid dispersion: dotenoroxetine 10.0g, povidone K90 80.0g, poloxamer 407 2.0g, i.e., drug loading ratio of 1:8.2, and the mass ratio of povidone K90 to poloxamer 407 is 40:1; Preparation method of dotenoroxetine solid dispersion: Accurately weigh 80.0 g of povidone K90 and 72.0 g of poloxamer 40, dissolve them in a 70% (v / v) ethanol aqueous solution prepared by 287 mL of pharmaceutical ethanol and 123 mL of purified water, stir until completely dissolved, add 10.0 g of dotenoroxetine, and continuously stir at 30°C until a clear and transparent mixed solution is formed. Spray dry the mixed solution using a spray dryer. The spray drying conditions include: inlet air temperature of 100°C, feed rate of 5 mL / min, and atomizing gas pressure of 200 kPa. After spray drying, collect the obtained powder, pass it through an 80-mesh sieve, and collect the material under the sieve to obtain dotenoroxetine solid dispersion with a yield of 92.5%.
[0044] The prescription for dotenoradine tablets is: dotenoradine solid dispersion (containing 2 mg of dotenoradine) 18.5 mg, microcrystalline cellulose 98 mg, croscarmellose sodium 8 mg, and magnesium stearate 2 mg.
[0045] Preparation method of dotenoradine tablets: According to the formulation of dotenoradine tablets, dotenoradine solid dispersion, microcrystalline cellulose and croscarmellose sodium are mixed evenly, then magnesium stearate is added and mixed for 5 minutes. The resulting mixture is compressed into tablets by direct compression method to obtain dotenoradine tablets, each containing 2 mg of dotenoradine.
[0046] Example 2 The formulation of dotenorazole solid dispersion: dotenorazole 11.0g, povidone K90 55.0g, poloxamer 407 5.5g, i.e., drug loading ratio of 1:5.5, and the mass ratio of povidone K90 to poloxamer 407 is 10:1; Preparation method of dotenoroxetine solid dispersion: The method in Example 1 was followed, and the yield of dotenoroxetine solid dispersion was 91.8%.
[0047] The prescription for dotenorazole tablets is as follows: dotenorazole solid dispersion (containing 2 mg of dotenorazole) 12.9 mg, microcrystalline cellulose 68 mg, croscarmellose sodium 10 mg, magnesium stearate 2 mg.
[0048] Preparation method of dotenolol tablets: The procedure is performed according to Example 1, and each dotenolol tablet contains 2 mg of dotenolol.
[0049] Comparative Example 1 In this comparative example, poloxamer 407 was omitted, and only povidone K90 was used as a single carrier to prepare dotenoroxetine solid dispersion. The specific formulation of dotenoroxetine solid dispersion was: 10.0 g of dotenoroxetine and 82.0 g of povidone K90. All other steps were performed according to the method in Example 1 to prepare dotenoroxetine solid dispersion and dotenoroxetine tablets respectively.
[0050] Comparative Example 2 The formulation of the dotenoroxetine solid dispersion in this comparative example is the same as that in Example 1, except that the dotenoroxetine solid dispersion is prepared by solvent evaporation, as detailed below: Accurately weigh 80.0 g of povidone K90 and 2.0 g of poloxamer 407, dissolve them in a 70% (v / v) ethanol aqueous solution prepared by 287 mL of pharmaceutical ethanol and 123 mL of purified water, stir until completely dissolved, add 10.0 g of dotenoradine, and continue stirring at 30°C until a clear and transparent mixed solution is formed; place the mixed solution on a rotary evaporator and evaporate under reduced pressure at a water bath at 60°C to remove the solvent, dry the obtained solid under vacuum at 40°C for 12 h, take it out, pulverize it, pass it through an 80-mesh sieve, and collect the material under the sieve to obtain dotenoradine solid dispersion, with a yield of 79.6%.
[0051] Dotenorazole tablets were then prepared using the dotenorazole solid dispersion following the procedure described in Example 1.
[0052] Comparative Example 3 The specific formulation of the dotenoroxetine solid dispersion in this comparative example is as follows: 10.0 g of dotenoroxetine, 1.0 g of povidone K90, and 41.0 g of poloxamer 407, i.e., the mass ratio of povidone K90 to poloxamer 407 is 1:1; all other steps were performed according to the method in Example 1 to prepare the dotenoroxetine solid dispersion and dotenoroxetine tablets respectively.
[0053] Comparative Example 4 The excipients used in this comparative example are povidone K30 and poloxamer 188. The specific formulation of the dotenoradine solid dispersion is: dotenoradine 10.0g, povidone K30 80.0g, and poloxamer 188 2.0g. Other components were prepared according to the method in Example 1 to obtain dotenoradine solid dispersion and dotenoradine tablets.
[0054] Comparative Example 5 The specific formulation of dotenoradine tablets in this comparative example is as follows: dotenoradine 2 mg, microcrystalline cellulose 98 mg, croscarmellose sodium 8 mg, magnesium stearate 2 mg; then, dotenoradine tablets were prepared according to the method in Example 1, with each tablet containing 2 mg of dotenoradine.
[0055] Test Example 1 The dissolution rate of dotenorazole tablets prepared in each example and comparative example was determined as follows: Test method: Method II (paddle method) of General Chapter 0931, Part IV, Chinese Pharmacopoeia 2020 Edition.
[0056] Dissolution medium: 900 mL of phosphate buffer solution with a pH of 6.8.
[0057] Rotation speed: 50 rpm.
[0058] Temperature: 37.0±0.5℃.
[0059] Sampling time: Take 5 mL samples at 5 min, 10 min, 15 min, 30 min, 45 min and 60 min respectively, and replenish with an equal amount of medium at the same temperature.
[0060] Analytical methods: The sample concentration was determined by HPLC, and the cumulative dissolution amount was calculated. Chromatographic conditions: C18 column (4.6 mm × 150 mm, 5 μm), mobile phase was triethylamine aqueous solution (pH 3.0) and acetonitrile, the volume ratio of triethylamine solution to acetonitrile was 50:50, the flow rate was 1.2 mL / min, the detection wavelength was 275 nm, and the column temperature was 40 °C.
[0061] Table 1 shows the dissolution test results of dotenoxam tablets prepared in each example and comparative example. The results show that there is no significant difference in effect between Example 1 and Example 2, indicating that the method of the present invention has good stability, and the dissolution rate and extent of Example 1 and Example 2 are much higher than those of the comparative examples. Specifically, compared with Comparative Example 1 (using only povidone K90), the dissolution rate of Example 1 jumped from 45.3% to 88.1% after adding poloxamer 407 in 15 minutes, proving that the combination of povidone K90 and poloxamer 407 has significant advantages. Compared with Comparative Example 4 (using povidone K30 and poloxamer 188), the effect of the present invention using specific excipients, namely povidone K90 and poloxamer 407, is also significantly better. Compared with Comparative Example 3 (the mass ratio of povidone K90 to poloxamer 407 is 1:1), the mass ratio of povidone K90 to poloxamer 407 in Example 1 is 40:1, and its dissolution effect is significantly better. Compared to Comparative Example 2 (solvent evaporation method), the dotenoradine tablets prepared by spray drying in this invention dissolve faster, indicating that the preparation process of this invention can more effectively achieve rapid dissolution of the drug (amorphous form). Compared to Comparative Example 5 (direct use of active pharmaceutical ingredient), this invention, by preparing dotenoradine into a dotenoradine solid dispersion, fundamentally changes the drug dissolution process, demonstrating significant practical value.
[0062] Table 1. Dissolution test results of dotenoradine tablets prepared in each example and comparative example (n=6, mean±SD)
[0063] Test Example 2 Accelerated stability tests were conducted on the dotenorazole tablets prepared in Example 1 and Comparative Examples 1-3. Specifically, the dotenorazole tablets were placed under accelerated test conditions (temperature 40℃±2℃, relative humidity 75%±5%RH) for 6 months, and samples were taken at 0 months, 3 months and 6 months to determine related substances and dissolution.
[0064] Table 2 shows the dissolution rate (%) and appearance changes of dotenoradine tablets prepared in Example 1 and Comparative Examples 1-3 after 45 minutes in the accelerated stability test. The results show that under the harsh accelerated stability test conditions, the dissolution rate of the dotenoradine tablets prepared in Example 1 remained basically unchanged, demonstrating excellent physical stability. This is attributed to the strong steric hindrance effect of povidone K90 and the synergistic effect of poloxamer 407, which effectively inhibited the crystallization of amorphous drugs. In contrast, the dissolution rate of dotenoradine tablets prepared in Comparative Examples 1-3 all showed a significant decreasing trend, indicating that their amorphous state was unstable and recrystallization had occurred.
[0065] Table 2. Dissolution, appearance changes, and related substances of dotenororil tablets at 45 min in accelerated stability test.
[0066] The results above show that the present invention has at least the following significant advantages compared with the prior art: (1) Significantly improved dissolution: The dotenorazole solid dispersion prepared by this invention has a dissolution rate and cumulative dissolution amount far higher than conventional formulations and single carrier formulations, achieving rapid and complete drug release.
[0067] (2) Excellent stability: Through the synergistic stabilizing effect of povidone K90 and poloxamer 407, this invention effectively inhibits the recrystallization of amorphous dotenoradine, ensuring the quality of the product within its shelf life.
[0068] (3) Minimal gastrointestinal irritation and high bioavailability: The rapid dissolution and absorption of dotenoradine in this invention reduces its retention time and concentration in the gastrointestinal tract, thereby reducing direct irritation to the mucosa and improving patient tolerance and compliance; at the same time, high dissolution directly translates into higher in vivo absorption, improving bioavailability.
[0069] (4) The process is simple, the cost is controllable, and it is suitable for industrial production: The present invention uses spray drying process and the combination of povidone K90 and poloxamer 407 to prepare dotenorolac solid dispersion, which effectively solves the problems of low solubility, poor bioavailability and poor stability of dotenorolac. Moreover, the process route is short, easy to control and scale up, and facilitates the development of oral solid dosage forms with high dissolution, stable quality and good patient compliance, which has significant economic and social benefits.
[0070] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A method for preparing a dotenoroxetine solid dispersion, comprising the following steps: Dotenorazole, povidone K90, and poloxamer 407 were dissolved in water and a pharmaceutical organic solvent to obtain a mixed solution; the mass ratio of povidone K90 to poloxamer 407 was >1. The mixed solution was spray-dried to obtain the dotenoroxetine solid dispersion.
2. The preparation method according to claim 1, characterized in that, The mass ratio of povidone K90 to poloxamer 407 is 10~40:
1.
3. The preparation method according to claim 2, characterized in that, The mass ratio of dotenorazole to the total mass of povidone K90 and poloxamer 407 is 1:5~9.
4. The preparation method according to claim 3, characterized in that, The pharmaceutical organic solvent includes ethanol, and the volume ratio of the pharmaceutical organic solvent to water is 2.0~2.5:1; the total mass fraction of dotenorazole, povidone K90 and poloxamer 407 in the mixed solution is 10~20%.
5. The preparation method according to any one of claims 1 to 4, characterized in that, The conditions for spray drying include: an inlet air temperature of 95~105℃, a feed rate of 4~6mL / min, and an atomizing gas pressure of 180~220kPa.
6. The dotenoroxetine solid dispersion prepared by the preparation method according to any one of claims 1 to 5.
7. A solid dispersion pharmaceutical composition comprising the dotenoroxetine solid dispersion of claim 6 and at least one pharmaceutically acceptable excipient.
8. Use of the dotenoroxetine solid dispersion of claim 6 or the solid dispersion pharmaceutical composition of claim 7 in the preparation of a medicament for the treatment of gout and / or hyperuricemia.
9. A drug containing a solid dispersion, wherein the raw materials for preparation include the dotenoroxetine solid dispersion of claim 6 or the solid dispersion drug composition of claim 7, wherein the drug containing the solid dispersion is an oral drug.
10. The drug containing a solid dispersion according to claim 9, characterized in that, The dosage form of the drug containing the solid dispersion includes tablets or capsules.
Citation Information
Cited By
A Dissolution Detection Method for Dotenoxetine Tablets
CN122567945A
